What is Poolbeg Pharma PLC's (POLB.L) StockRank?

MoatMap's StockRank for Poolbeg Pharma PLC (POLB.L) is 39/100, with a Hold signal. This is a composite score combining Quality (27), Value (35), and Momentum (69) factor ranks across MoatMap's 20,000+ stock universe.

Does Poolbeg Pharma PLC have an economic moat?

Poolbeg Pharma PLC (POLB.L) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Poolbeg Pharma PLC a buy, hold, or sell?

MoatMap's current signal for Poolbeg Pharma PLC (POLB.L) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Poolbeg Pharma PLC in?

Poolbeg Pharma PLC (POLB.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

POLB.L

HOLDREMOVE

Poolbeg Pharma PLC · Healthcare · United Kingdom · $56M · Avg Vol: $280K/d

StockRank

P/E (TTM)

—

ROE

-63.7%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A micro-cap, clinical-stage biopharma company that is highly speculative, pre-revenue, and does not meet any Terry Smith quality or Warren Buffett moat criteria.

COMPANY DESCRIPTION

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address infectious diseases and other prevalent medical conditions. The company utilizes an asset-light, capital-efficient business model, leveraging AI-driven data analysis to identify and in-license promising clinical-stage assets for rapid development and partnering. Its competitive moat is supported by a proprietary database of human challenge trial data and a highly experienced leadership team with a track record of successful pharma exits.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.01	-0.01	-0.02	-0.01	—
Shares	500M	500M	500M	697M	+39.4%
Debt	1M	1M	1M	2M	11.6%
Equity	25M	19M	12M	12M	-22.3%
Op CF	-6M	-6M	-6M	-6M	—
Inv CF	-520,896	481,963	401,412	232,255	—
Fin CF	0	0	0	6M	—

PRICE (1M)+67.0%

SMA 50SMA 200

$0.10

RSI (14)

69.0

52W High

$0.12

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-65.9%9.4

ROE

-63.7%13.6

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-27.8%10.7

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

6.17x77.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-7.4x78.0

P/FCF

—N/A

P/B

6.4x18.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

84%80.2

RS 6M

99%97.5

SMA 50/200

1.25x91.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+5%23.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$56M

P/E (Forward)

-8.1x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of POLB.L are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
POLB.L	Poolbeg Pharma PLC(you)	$56M	39	HOLD
IXI.L	IXICO plc	$25M	29	SELL
HEMO.L	Hemogenyx Pharmaceuticals Plc	$63M	14	STRONG SELL
SBTX.L	SkinBioTherapeutics plc	$34M	21	SELL
SAR.L	Sareum Holdings plc	$47M	14	STRONG SELL
AREC.L	Arecor Therapeutics plc	$34M	59	HOLD
SCLP.L	Scancell Holdings plc	$333M	37	HOLD
IMM.L	ImmuPharma plc	$37M	1	STRONG SELL
4BB.L	4basebio PLC	$110M	5	STRONG SELL
APTA.L	Aptamer Group PLC	$28M	3	STRONG SELL

Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%

Poolbeg Pharma PLC (POLB.L) — Stock Score Summary

Poolbeg Pharma PLC (POLB.L) has a MoatMap StockRank of 39/100 based on Quality (27/100), Value (35/100), and Momentum (69/100) factor scores. The current signal is HOLD. A micro-cap, clinical-stage biopharma company that is highly speculative, pre-revenue, and does not meet any Terry Smith quality or Warren Buffett moat criteria.

Key Financial Metrics

Price	$0.10
Market Cap	$56M
P/E (Forward)	-8.12
Price/Book	6.42
Return on Equity	-63.7%
Return on Invested Capital	-65.9%
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-5M

Poolbeg Pharma PLC operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Poolbeg Pharma PLC’s (POLB.L) StockRank?: MoatMap’s StockRank for Poolbeg Pharma PLC (POLB.L) is 39/100, with a Hold signal. It is a composite of Quality (27), Value (35), and Momentum (69) factor ranks across MoatMap’s 20,000+ stock universe.
Does Poolbeg Pharma PLC have an economic moat?: Poolbeg Pharma PLC (POLB.L) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Poolbeg Pharma PLC a buy, hold, or sell?: MoatMap’s current signal for Poolbeg Pharma PLC (POLB.L) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Poolbeg Pharma PLC in?: Poolbeg Pharma PLC (POLB.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).